Everest Medicines

Everest Medicines is a biotechnology and pharmaceutical company founded in 2017, headquartered in the United States. The company's slogan, "Better Medicines, Better Life," encapsulates its dedication to developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. With a focus on addressing critical unmet medical needs for patients in Greater China, the company has garnered significant attention from investors. The Everest Medicines team boasts deep expertise and an extensive track record in clinical development, regulatory affairs, CMC, business development, and operations both in China and with leading global pharmaceutical companies. This solid foundation has positioned the company as the partner of choice for innovative firms worldwide looking to enter the Asian pharmaceutical market. In 2020, the company's Series C investment round, amounting to a substantial $310.00M, attracted investments from a notable group of investors, including HBM Healthcare Investments, RA Capital Management, CBC Group, Decheng Capital, Janchor Partners, Janus Handerson, Octagon Capital Advisors, Rock Springs Capital, Hillhouse Investment, Jiashan SDIC. This funding reflects confidence in Everest Medicines' mission and approach. With its strong financial backing and strategic partnerships, Everest Medicines is poised to make a significant impact in the biotechnology and pharmaceutical industries—delivering better medicines and ultimately improving lives in Asia and beyond.